Compartilhar
Informação da revista
Vol. 94. Núm. 6.
Páginas 773-774 (1 novembro 2019)
Compartilhar
Compartilhar
Baixar PDF
Mais opções do artigo
Visitas
5759
Vol. 94. Núm. 6.
Páginas 773-774 (1 novembro 2019)
Correspondence
Open Access
Sepsis assessment in SJS/TEN: an important point overlooked?
Visitas
5759
Ananta Khuranaa,
Autor para correspondência
drananta2014@gmail.com

Corresponding author.
, Mukesh Kumar Sharmab, Kabir Sardanaa
a Department of Dermatology, Dr. RML Hospital, PGIMER, New Delhi, India
b Department of Burns, Plastic and Maxillofacial Surgery, Dr. RML Hospital, PGIMER, New Delhi, India
Conteúdo relacionado
Carlos Gustavo Wambier, Sarah Perillo de Farias Wambier
Este item recebeu

Under a Creative Commons license
Informação do artigo
Texto Completo
Bibliografia
Baixar PDF
Estatísticas
Texto Completo
Dear Editor,

We read the study “Epidermal necrolysis: SCORTEN performance in AIDS and non-AIDS patients”1 with interest and congratulate the authors for their important work. We would like to highlight a point regarding the utility of SCORTEN in epidermal necrolysis. The authors rightly point out that generalized infections and sepsis are the major causes of mortality in SJS/TEN patients. However, SCORTEN does not include any direct marker of the infective state. It assesses parameters that may indicate infection or just reflect the ongoing systemic inflammatory response. Unfortunately, sepsis may have already set in at the time of admission. It is essential to know the infection status at presentation, both for prognostication and for deciding specific management. A delay in diagnosis of sepsis can result in rapid progression to circulatory collapse and organ failure. Further, any form of iatrogenically induced immunosuppression may be fatal for a septic patient. Awaiting cultures may postpone important decisions and may not always give an accurate picture. Non-specific markers, such as C-reactive protein, erythrocyte sedimentation rate, total leucocyte count, and platelet count share similar concerns. An ideal marker for early sepsis diagnosis needs to be sensitive, specific, rise early in the course of sepsis, produce reliable and reproducible results, and be easy to measure in a hospital setting. The available parameter that comes closest to these criteria is probably serum procalcitonin (PCT). The reactive pattern of PCT has an onset within four hours of response to infection or injury, peaks at six hours with a plateau of eight to 24h, then returns to baseline in two to three days.2 The normal levels of PCT are about 0.05ng/mL. Higher levels, up to 0.5ng/mL, occur in local infections, 0.5–2ng/mL in systemic infections, 2–10ng/mL in sepsis, and >10ng/mL in severe sepsis.3

The utility of PCT for sepsis determination has been largely established in burn patients.2,4 A similar systemic inflammatory response occurs in TEN, making differentiation from sepsis difficult. We have observed that a very high PCT value within 24h of admission (>10ng/mL) is a predictor of worse outcomes, irrespective of the SCORTEN value in the same time frame. Similar observations have been made by Mokline et al. in burn patients.2

Thus, we believe that day 0 PCT levels should be considered as an independent prognostic marker for SJS/TEN in addition to the validated parameters of SCORTEN. Further, we encourage trials specifically evaluating the role of PCT in the management of SJS/TEN.

Financial support

None declared.

Authors’ contribution

Ananta Khurana: Approval of the final version of the manuscript; critical literature review; effective participation in research orientation; critical manuscript review; preparation and writing of the manuscript.

Mukesh Kumar Sharma: Approval of the final version of the manuscript; critical literature review; critical manuscript review; preparation and writing of the manuscript.

Kabir Sardana: Approval of the final version of the manuscript; critical literature review; effective participation in research orientation; critical manuscript review; preparation and writing of the manuscript.

Conflicts of interest

None declared.

References
[1]
C.G. Wambier, T.A. Hoekstra, S.P.F. Wambier, R. Bueno Filho, F.C. Vilar, R.S. Paschoal, et al.
Epidermal necrolysis: SCORTEN performance in AIDS and non-AIDS patients.
An Bras Dermatol, 94 (2019), pp. 17-23
[2]
E.A. Mann, G.L. Wood, C.E. Wade.
Use of procalcitonin for the detection of sepsis in the critically ill burn patient: a systematic review of the literature.
[3]
A. Mokline, L. Garsallah, I. Rahmani, K. Jerbi, H. Oueslati, S. Tlaili, et al.
Procalcitonin: diagnostic and prognostic biomarker of sepsis in burned patients.
Ann Burns Fire Disasters, 28 (2015), pp. 116-120
[4]
L. Cabral, V. Afreixo, L. Almeida, J.A. Paiva.
The use of procalcitonin (PCT) for diagnosis of sepsis in burn patients: a meta-analysis.

How to cite this article: Khurana A, Sharma MK, Sardana K. Sepsis assessment in SJS/TEN: an important point overlooked? An Bras Dermatol. 2019;94:773–4.

Study conducted at the Dr. RML Hospital, PGIMER, New Delhi, India

Baixar PDF
Idiomas
Anais Brasileiros de Dermatologia (Portuguese)
Opções de artigo
Ferramentas
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.